Samik Pharm삼익제약

Samik Pharm is a small Korean generic drug maker that swung to a net loss in the first half of 2026 despite a small operating profit.

Trailing revenue is about ₩62.3B with an operating profit of ₩1.8B (2.9% margin) but a net loss of ₩1.3B, according to the latest filings through H1 2026. The shares closed at ₩7,160 on 2026-10-26, down 20.8% over one month but up 53.2% over three months, and the company listed on KOSDAQ in late October 2025. The data does not give a P/E ratio, and the company's own profile describes it mainly as a prescription drug maker with a contract manufacturing business.

What stands out

• Trailing free cash flow was negative at about -₩2.4B, even though the company holds ₩7.5B in cash and has no borrowings.
• The 2025 full-year figures showed a 5.5% operating margin and a net loss of ₩0.8B, so profitability has weakened into 2026.
• The DCF-based fair value model gives a base of ₩4,850, a bear of ₩3,166 and a bull of ₩8,030, all below or around the current price in the bear case; this is a model output, not a forecast.
• Recent news centred on a hair-loss drug trial result by a partner company, which lifted the shares 17% or more on 2026-10-20.
• Foreign ownership is only 1.3% and was unchanged over 60 days, while foreign investors net sold about ₩1.0B over the last 20 days.

What to watch

• The next periodic results and whether the H1 2026 net loss continues into the full year.
• The Veradermix hair-loss drug Phase 3 news flow, since the recent share rally was tied to it and the data does not show how much revenue it could contribute.
• Further 5%+ holding reports and insider shareholding filings, given the shares' large swings over the past year.